These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 9071478

  • 1. Alendronate in the treatment of Paget's disease of bone.
    Khan SA, Vasikaran S, McCloskey EV, Benéton MN, Rogers S, Coulton L, Orgee J, Coombes G, Kanis JA.
    Bone; 1997 Mar; 20(3):263-71. PubMed ID: 9071478
    [Abstract] [Full Text] [Related]

  • 2. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
    Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ.
    Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
    [Abstract] [Full Text] [Related]

  • 3. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone.
    O'Doherty DP, Gertz BJ, Tindale W, Sciberras DG, Survill TT, Kanis JA.
    J Bone Miner Res; 1992 Jan; 7(1):81-7. PubMed ID: 1549961
    [Abstract] [Full Text] [Related]

  • 4. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
    Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):961-7. PubMed ID: 8772558
    [Abstract] [Full Text] [Related]

  • 5. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
    Adami S, Zamberlan N, Mian M, Dorizzi R, Rossini M, Braga B, Gatti D, Bertoldo F, Locascio V.
    Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed.
    Filipponi P, Pedetti M, Beghe F, Giovagnini B, Miam M, Cristallini S.
    Bone; 1994 May; 15(3):261-7. PubMed ID: 8068446
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of Paget's disease of bone with alendronate.
    Lombardi A.
    Bone; 1999 May; 24(5 Suppl):59S-61S. PubMed ID: 10321931
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH.
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [Abstract] [Full Text] [Related]

  • 13. Diphosphonates in Paget's disease.
    Russell RG, Smith R, Preston C, Walton RJ, Woods CG.
    Lancet; 1974 May 11; 1(7863):894-8. PubMed ID: 4133419
    [No Abstract] [Full Text] [Related]

  • 14. Sustained response to intravenous alendronate in postmenopausal osteoporosis.
    Vasikaran SD, Khan S, McCloskey EV, Kanis JA.
    Bone; 1995 Dec 11; 17(6):517-20. PubMed ID: 8835304
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG, Lim EM, Kent GN, Ward LC, Gutteridge DH.
    J Bone Miner Res; 2001 Sep 11; 16(9):1719-23. PubMed ID: 11547843
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology].
    Chapuy MC, Meunier P, Terrier M, David L, Vignon G.
    Pathol Biol (Paris); 1975 May 11; 23(5):349-59. PubMed ID: 172838
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
    Reginster JY, Colson F, Morlock G, Combe B, Ethgen D, Geusens P.
    Arthritis Rheum; 1992 Aug 11; 35(8):967-74. PubMed ID: 1642662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.